Treatment of neonatal abstinence syndrome

Tran, Jennifer H

doi:10.1016/s0891-5245(99)90023-8

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanovskaya et al [30] observed that transplacental transfer of buprenorphine was low but also found high intra-individual and low inter-individual variability in plasma drug levels in pregnant women. Another factor causing variability in severity of NAS involves the infant's ability to metabolize drugs [31]. In a study involving 23 buprenorphine-exposed infants, Marquet [19] found that the mean duration of morphine treatment was 16.5 days (range 1-36).…”

Section: Discussionmentioning

confidence: 99%

Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone

et al. 2007

View full text Add to dashboard Cite

This hospital morphine solution is adequate for management of NAS. Preparations showed good stability and doses could be adjusted with a margin of 0.02 mg. The onset of NAS occurred within 24 h after birth in methadone-exposed infants (range 6-24 h) and within 48 h after birth in buprenorphine-exposed infants (range 24-168 h). Due to the possibility of delayed onset of NAS up to 7 days, infants born to mothers treated with buprenorphine should be kept in the hospital for an appropriate surveillance period. Treatment time was significantly longer (45 vs. 28 days) and the mean morphine doses were higher (1.7 fold) in methadone-exposed than buprenorphine-exposed infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Options such as phenobarbital, clonidine, diazepam, and chlorpromazine were tested. As stated before, diazepam was reported to be associated with a number of concerning adverse effects as well as withdrawal symptoms after treatment [89], similarly to what occurs with chlorpromazine, which has been associated to cerebellar dysfunction as well as hematological problems [82]. In the case of clonidine, a randomized clinical trial performed between 2002 and 2005, where 80 infants were enrolled, showed a significant decrease (27%) in length of therapy (when compared to placebo), lower dosages of opioid drug needed for treatment, and no treatment failure in the clonidine group.…”

Section: Neonatal Abstinence Syndrome—treatmentmentioning

confidence: 99%

Opioid Use in Pregnant Women and Neonatal Abstinence Syndrome—A Review of the Literature

Martins

Oppolzer

Santos

et al. 2019

Toxics

View full text Add to dashboard Cite

Opiate use during pregnancy has been an increasing problem over the last two decades, making it an important social and health concern. The use of such substances may have serious negative outcomes in the newborn, and clinical and cognitive conditions have been reported, including neonatal abstinence syndrome, developmental problems, and lower cognitive performance. These conditions are common when opiates are used during pregnancy, making the prescription of these kinds of drugs problematic. Moreover, the mother may develop opiate addiction, thus, increasing the likelihood of the infant being born with any of those conditions. This paper reviews the use of opiates during pregnancy and focuses mainly on the neonatal abstinence syndrome. First, the commonly prescribed opiates will be identified, namely those usually involved in cases of addiction and/or neonatal abstinence syndrome. Second, published approaches to deal with those problems will be presented and discussed, including the treatment of both the mother and the infant. Finally, we will outline the treatments that are safest and most efficient, and will define future goals, approaches, and research directions for the scientific community regarding this problem.

show abstract

“…Tran et al. noticed a short duration of treatment averaging 13 days when treating neonatal abstinence syndrome with clonidine (6). To date, the only controlled and randomized trial was conducted by Agthe et al.…”

Section: Introductionmentioning

confidence: 99%

“…In six out of seven patients, alleviation of symptoms of withdrawal was achieved with a daily oral dosage of 3-4 lg clonidine ⁄ kg (5). Tran et al noticed a short duration of treatment averaging 13 days when treating neonatal abstinence syndrome with clonidine (6). To date, the only controlled and randomized trial was conducted by Agthe et al They employed clonidine as an adjunct to opiates in treating neonatal abstinence syndrome (7).…”

Section: Introductionmentioning

confidence: 99%